Here, we have performed a preclinical validation of the drug by administering intraperitoneally niclosamide in two different ALS mouse models, i.e., SOD1-G93A and FUS, that recapitulate ALS key pathological and biological processes [20]. Here, SOD1 is linked to amyotrophic lateral sclerosis.